Clinical Outcome of Targeted Therapy with Gefitinib in Metastatic NSCLC Depending on the Type of EGFR Mutation: A REASON Subgroup Analysis by Exon

被引：0
|
作者：
Schuette, W. [1 ]
Thomas, M. [2 ]
Eberhardt, W. [3 ]
Zirrgiebel, U. [4 ]
Radke, S. [5 ]
Dietel, M. [6 ]
机构：
[1] Krankenhaus Martha Maria, Halle, Saale, Germany
[2] Univ Klinikum, Thoraxklin, Heidelberg, Germany
[3] Univ Klinikum, Med Onkol, Essen, Germany
[4] iOMEDICO AG, Freiburg, Germany
[5] AstraZeneca GmbH, Wedel, Germany
[6] Humboldt Univ, Pathol Inst, D-10099 Berlin, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0341
引用
收藏
页码：120 / 120
页数：1
相关论文
共 41 条
  • [1] Exon-dependent Subgroup-analysis of the Non-interventional REASON-Study: PFS and OS in EGFR-mutated NSCLC Patients Treated with Gefitinib or Chemotherapy
    Schuette, W.
    Dietel, M.
    Thomas, M.
    Eberhardt, W.
    Griesinger, F.
    Zirrgiebel, U.
    Radke, S.
    Schirmacher, P.
    PNEUMOLOGIE, 2016, 70 (08): : 514 - 521
  • [2] Gefitinib/Chemotherapy vs Chemotherapy in EGFR Mutation-Positive NSCLC Resistant to First-Line Gefitinib: IMPRESS T790M Subgroup Analysis
    Soria, Jean-Charles
    Kim, Sang-We
    Wu, Yi-Long
    Nakagawa, Kazuhiko
    Yang, Jin-Ji
    Ahn, Myung-Ju
    Wang, Jie
    Yang, James Chih-Hsin
    Lu, You
    Atagi, Shinji
    Ponce, Santiago
    Shi, Xiaojin
    Taylor, Rosemary
    Jiang, Haiyi
    Thress, Kenneth
    Mok, Tony
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S207 - S208
  • [3] Pooled analysis of clinical outcome for EGFR TKI-treated patients with EGFR mutation-positive NSCLC
    Paz-Ares, Luis
    Soulieres, Denis
    Moecks, Joachim
    Bara, Ilze
    Mok, Tony
    Klughammer, Barbara
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2014, 18 (08) : 1519 - 1539
  • [4] The characteristics and clinical outcome of metastatic NSCLC harboring uncommon EGFR mutation at Thailand's tertiary referral center
    Chantharasamee, J.
    Poungvarin, N.
    Danchaivijitr, P.
    Techawatanawanna, S.
    ANNALS OF ONCOLOGY, 2018, 29 : 525 - 525
  • [5] ELDERLY CHEMOREFRACTORY NSCLC PATIENTS DERIVE BENEFIT FROM SALVAGE TARGETED THERAPY - SUBGROUP ANALYSIS OF CLINICAL OUTCOME AND TOXICITY FROM THE BATTLE TRIAL
    Tsao, Anne
    Liu, Suyu
    Lee, J. J.
    Alden, Christine
    Kim, Edward
    Blumenschein, George
    Herbst, Roy
    Lippman, Scott
    Wistuba, Ignacio
    Hong, Waun K.
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S557 - S557
  • [6] CORRELATION ANALYSIS OF EGFR GENE MUTATION FREQUENCY AND RESISTANCE TO GEFITINIB TARGETED THERAPY IN NON-SMALL CELL LUNG CANCER
    Gao, Bo
    Xiao, Wendi
    Shi, Rui
    ACTA MEDICA MEDITERRANEA, 2023, 39 (02): : 509 - 513
  • [7] Clinical Response to Osimertinib in a Patient with Metastatic NSCLC Harboring EGFR A763_Y764insFQEA Exon 20 Insertion Mutation: A Case Report
    Montenegro, G. Bravo
    Kim, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S575 - S576
  • [8] Clinical outcome of treatment with pemetrexed/cisplatin in patients with EGFR-mutation negative (EGFR-) metastatic non-small cell lung cancer (NSCLC)
    Storozhakova, Anna E.
    Vladimirova, Liubov Yu
    Kit, Oleg Ivanovich
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [9] Do elderly chemorefractory NSCLC patients derive benefit from salvage targeted therapy? Subgroup analysis of clinical outcome and toxicity from the BATTLE trial.
    Tsao, A. S.
    Liu, S.
    Lee, J. J.
    Alden, C. M.
    Kim, E. S.
    Blumenschein, G. R.
    Herbst, R. S.
    Lippman, S. M.
    Wistuba, I. I.
    Hong, W. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] Afatinib versus Gefitinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients Aged ≥75 Years: Subgroup Analysis of LUX-Lung 7
    Park, Keunchil
    Tan, Eng Huat
    Zhang, Li
    Hirsh, Vera
    O'Byrne, Ken
    Boyer, Michael
    Yang, James Chih-Hsin
    Mok, Tony
    Peil, Barbara
    Maerten, Angela
    Paz-Ares, Luis
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1214 - S1214
12345